CSL Behring disclosed a “temporary global stockout” of its gene therapy for hemophilia B that it says could delay treatment for some patients. In a

AstraZeneca has added more details on how it will use its $15 billion budget to expand in China — and the UK pharma is betting

Collegium Pharmaceutical is beefing up its portfolio in ADHD with the acquisition of Corium’s FDA-approved drug Azstarys. The $650 million upfront deal carries up to

Pfizer said a combination of two of its prostate cancer drugs — Talzenna and Xtandi — succeeded in a Phase 3 study and that it

Eli Lilly has positive phase 3 results for its triple agonist retatrutide in diabetes to go with its earlier encouraging data in obesity.